Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Cellectar Biosciences, Inc.

CLRB · Nasdaq · CIK 0001279704 · Healthcare · Biotechnology

INSIDER SIGNAL

42.9 / 100

2 buyers · 2 purchase transaction lines · $50.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+5.2 / 25
Role+13.0 / 20
Recency+0.7 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Longcor JarrodChief Operating Officer
●
CARUSO JAMES VChief Executive Officer
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION50%Largest buyer: Longcor Jarrod · $25.0K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-05-07–2026-05-07

Roles in the peak window: Chief Executive Officer, Chief Operating Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

42.9 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 43.1
  2. 43.0
  3. 43.0
  4. 42.9
  5. 42.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

2Purchases
1Sales
0Other Form 4 lines
3SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-38.8%
3M
-44.9%
6M
-47.5%
12M
-69.7%

Volatility & liquidity

Volatility
110.8%
Beta
—
Avg daily value
USD 91,527

Valuation

Market cap
USD 13.7M
P/E
—

Fundamentals

Profit margin
—
ROE
-255.2%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-11 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
166,265
Previous report
191,128
Avg daily volume
81,288
Days to cover
2.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-07Longcor JarrodPurchase (P)Common Stock8,680USD 2.88USD 24,998SEC filing ↗
2026-05-07CARUSO JAMES VPurchase (P)Common Stock8,680USD 2.88USD 24,998SEC filing ↗
2025-07-02Longcor JarrodPurchase (P)Common Stock10,000USD 4.99USD 49,900SEC filing ↗
2025-07-02Kolean Chad JPurchase (P)Common Stock5,000USD 4.99USD 24,950SEC filing ↗
2025-07-02CARUSO JAMES VPurchase (P)Common Stock10,000USD 4.99USD 49,900SEC filing ↗
2025-01-10Longcor JarrodPurchase (P)Common Stock30,000USD 0.28USD 8,400SEC filing ↗
2021-09-14Swirsky Douglas JPurchase (P)Common Stock25,000USD 1.04USD 26,000SEC filing ↗
2021-09-03DRISCOLL FREDERICK WPurchase (P)Common Stock19,417USD 1.04USD 20,194SEC filing ↗
2021-03-04CARUSO JAMES VPurchase (P)Common Stock5,100USD 1.70USD 8,670SEC filing ↗
2020-12-28Longcor JarrodPurchase (P)Common Stock29,630USD 1.35USD 40,000SEC filing ↗
2020-12-28Elefant DovPurchase (P)Common Stock7,407USD 1.35USD 9,999SEC filing ↗
2020-12-28CARUSO JAMES VPurchase (P)Common Stock37,037USD 1.35USD 50,000SEC filing ↗
2020-06-05Longcor JarrodPurchase (P)Common Stock65,218USD 1.15USD 75,001SEC filing ↗
2020-06-05Elefant DovPurchase (P)Common Stock4,348USD 1.15USD 5,000SEC filing ↗
2020-06-05CARUSO JAMES VPurchase (P)Common Stock21,740USD 1.15USD 25,001SEC filing ↗

Form 4 evidence

3 transaction lines in the latest 365-day window; 25 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-07Longcor JarrodPurchase (P)Common Stock8,680USD 2.88USD 24,998SEC filing ↗
2026-05-07CARUSO JAMES VPurchase (P)Common Stock8,680USD 2.88USD 24,998SEC filing ↗
2025-12-12NEIS JOHNSale (S)Common Stock198USD 3.70USD 733SEC filing ↗
Show recent Form 4 evidence (3 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-07Longcor JarrodPurchase (P)Common Stock8,680USD 2.88USD 24,998SEC filing ↗
2026-05-07CARUSO JAMES VPurchase (P)Common Stock8,680USD 2.88USD 24,998SEC filing ↗
2025-12-12NEIS JOHNSale (S)Common Stock198USD 3.70USD 733SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCLRB
CIK0001279704
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history25 transaction lines from 2020-02-03 to 2026-05-07
16 P purchase lines · 1 S sale lines · 8 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.